Rybrevant Faspro combination demonstrates 77% ORR in first-line treatment of advanced head and neck cancer, phase II study finds

In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase III open-label, multicenter, randomized DeLLphi-305 study.

Perioperative Imfinzi (durvalumab) plus neoadjuvant Padcev (enfortumab vedotin) reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer, according to the VOLGA phase III trial. The combination demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of event-free survival and key secondary endpoint of overall survival in patients with muscle-invasive bladder cancer versus standard of care.